Items filtered by date: February 2014

 

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

This analysis estimates that apixaban has an incremental cost-effectiveness ratio of £11,909 per QALY gained compared with warfarin (in VKA suitable patients) and £7,196 per QALY gained compared with aspirin (in VKA unsuitable patients) for stroke prevention in AF. This analysis estimates that apixaban has an incremental cost-effectiveness ratio of £11,909 per QALY gained compared with warfarin (in VKA suitable patients) and £7,196 per QALY gained compared with aspirin (in VKA unsuitable patients) for stroke prevention in AF.

http://eurheartj.oxfordjournals.org/content/early/2014/02/07/eurheartj.ehu006.abstract

 

Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

This statement summarises data on stroke risk factors that are unique to (reproductive factors) and more common (migraine with aura, obesity, metabolic syndrome, and AF) in women than men, and expands on data provided in prior guidelines for women.

http://stroke.ahajournals.org/content/early/2014/02/06/01.str.0000442009.06663.48.abstract

 

Meta-Analysis of Risk of Stroke or Transient Ischemic Attack With Dabigatran for Atrial Fibrillation Ablation

A meta-analysis (18 observational studies; n= 5513) found that dabigatran during AF ablation is associated with a higher risk of thromboembolic complications compared to warfarin (16 vs 7 events; OR 2.81, 95% CI 1.23 to 6.45) with no significant differences for major bleeding.

http://www.sciencedirect.com/science/article/pii/S0002914914000538

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service.
Further details on this service can be found at: http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

 

Published in News